2016 CMHC - Professional Medical Education (non-CME)

Boston 2016

Attend Professional Education Symposia

Round out your CMHC educational experience by attending Professional Education symposia focused on novel therapies and diagnostic testing. These non-certified activities are not part of the official CMHC program and are planned solely by the sponsoring organizations/companies. There are no fees to attend and meals or refreshments may be provided. Register for the CMHC today to sign up for these activities.

Wednesday, October 5, 2016

Non-CME Lunch Symposium
12:15pm - 1:30pm

Insights on Repatha® (evolocumab): A Clinical Perspective

Presenters: Yehuda Handelsman, MD, FACP, FACE, FNLA

Reduction in circulating levels of low-density lipoprotein cholesterol (LDL-C) remains fundamental to major cholesterol treatment guidelines and recommendations. Nonetheless, despite available treatment over 70% of patients with CHD in the United States did not achieve an LDL-C level below 70 mg/dL. Patients with familial hypercholesterolemia (FH) may also require additional LDL-C reduction. This program will review a current therapy for additional LDL-C lowering.

Sponsored by Amgen Inc.

Wednesday, October 5, 2016

Non-CME Dinner Reception
6:00pm - 7:00pm

Examining Options to Go Further in the Treatment of Adults with T2DM

Presenters: Cres Miranda, MD

This program will cover the following topics regarding a sodium-glucose co-transporter (SGLT2) inhibitor: the role of the kidney in regulation of hyperglycemia in T2DM, the mechanism of action – mediated inhibition of SGLT2 in the proximal convoluted tubule of the kidney, key efficacy and safety data from active-controlled clinical trials, Important Safety Information, question and answer session. This promotional educational activity is sponsored by Janssen Pharmaceuticals, Inc. It is not certified for continuing medical education.

Sponsored by Janssen Pharmaceuticals, Inc.

Thursday, October 6, 2016

Non-CME Session
5:30pm - 6:30pm

Widespread Lack or Loss of Adipose Tissue and Metabolic Abnormalities – Could it Be Generalized Lipodystrophy?

Presenters: Tamer Yacoub, MD

Join us to learn about generalized lipodystrophy (GL), a disorder characterized by the widespread lack or loss of body fat resulting in severe metabolic abnormalities. This program includes a review of the etiology and pathophysiology of GL, metabolic abnormalities and serious comorbidities associated with GL and key criteria to identify and diagnose GL.

Sponsored by Aegerion Pharmaceuticals, Inc.

Thursday, October 6, 2016

Non-CME Session
5:30pm - 6:30pm

Pure EPA: Mechanism and Clinical Data

Presenters: Matthew Budoff, MD

Hear an expert medical presentation entitled Pure EPA: Mechanism and Clinical Data, which provides a brief overview of the atherogenicity of TGs and TG-rich lipoproteins and the potential impact on CV risk, despite statin-controlled LDL-C. The clinical program for pure EPA VASCEPA® (icosapent ethyl), including the ongoing CV outcome trial REDUCE-IT, will be reviewed. In the treatment of patients with elevated TGs, the clinical effects between EPA and DHA omega-3s and the deficiencies of fish oil supplements will be discussed.

Sponsored by Amarin Pharma, Inc.

Back to 11th Annual CMHC Home